Full-Time
Site Coordinator
Haleon
10,001+ employees
Global consumer health care products company
No salary listed
Bengaluru, Karnataka, India
In Person
 Administrative & Executive Assistance (1) |
|---|
Get referred to Haleon
See people who can refer or advise you
- Experience within an enterprise information technology or technology organization.
- Knowledge of workplace technology and audio-visual systems.
- Experience supporting executive events or leadership meetings.
- Proven experience as an Executive Assistant or similar administrative role, preferably within a technology or information technology department.
- Experience with executive stakeholder management.
- Ability to manage complex calendars, prioritize workloads, and multitask under pressure.
- Ability to handle confidential information with discretion.
- Strong organizational skills.
- Experience with Microsoft Outlook Calendar and Email.
- Advanced skills in Microsoft Office Suite, including Word, Excel, and PowerPoint.
- Experience with Microsoft Forms and SharePoint.
- Plan, coordinate, and manage visits from the Chief Technology Officer, executive leadership team, customers, and other senior stakeholders.
- Develop detailed visit agendas and schedules in partnership with Executive Assistants and business leaders.
- Ensure meeting rooms, collaboration spaces, audio-visual equipment, and technology are fully operational before each visit.
- Coordinate catering, visitor access, security requirements, transport, and accommodation where required.
- Act as the on-site host and primary point of contact during executive visits.
- Anticipate and resolve logistical issues to ensure a seamless visitor experience.
- Maintain site readiness by ensuring meeting areas, collaboration spaces, and demonstration environments are prepared and presentable.
- Coordinate with Facilities, Workplace Services, Security, and information technology support teams to resolve site-related issues.
- Monitor site requests and coordinate timely completion of actions.
- Support office events, leadership meetings, town halls, and employee engagement activities.
- Arrange team meals for department-building and morale activities.
- Coordinate logistics for technology town halls, including scheduling, venue and room setup, catering, and slide deck collection.
- Plan and execute internal and external technology events, managing vendor communications, attendee lists, and on-the-day logistics.
- Manage executive calendars using Microsoft Outlook, coordinating internal and external meetings across multiple time zones.
- Create and manage departmental distribution lists.
- Book flights, hotels, and transportation through Concur while ensuring cost efficiency and adherence to travel policy.
- Prepare, submit, and track expense reports using Concur.
- Draft, proofread, and send professional emails and communications on behalf of executives.
- Maintain and organize departmental SharePoint sites, ensuring document accessibility and accurate version control.
- Project management or coordination certification is advantageous.
- Experience as an Executive Assistant or similar administrative professional within a technology or information technology department is preferred.
Haleon is a global consumer health company that develops and sells everyday health products under brands such as Sensodyne, Advil, and Centrum. Its products address oral care, pain relief, immunity, and general well-being, working through science-backed formulations people use daily. Haleon differentiates itself by being a focused, standalone consumer health business formed from GSK’s spin-off and built from leading brands through major acquisitions, operating at scale with a portfolio of category leaders and competing with peers like Kenvue and Procter & Gamble. Its goal is to help people take control of their daily health with trusted products, while expanding its global reach and investing in manufacturing capacity and brand development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Weybridge, United Kingdom
Founded
2022
Get referred to Haleon
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 operating margin reached 24.3%, up 120 basis points on productivity.
- North America returned to 3.1% growth in Q2 2026, driven by shelf resets and e-commerce.
- Panacombo launched July 29, 2026, expanding Haleon's pain-relief franchise with dual-action tablets.
What critics are saying
- H1 2026 organic growth of 2.6% sits below Haleon's 4% to 6% target.
- Respiratory sales and Europe, Dubai, and Pakistan weakened sharply in July 2026.
- The 2036-debt refinancing raises interest expense, while weak innovation can commoditize premium brands.
What makes Haleon unique
- Haleon owns category leaders Sensodyne, Advil, Panadol, Centrum, and Voltaren across 170 markets.
- Its pharmacy-channel relationships and healthcare-professional trust create durable shelf access and recommendation power.
- The June 2026 Microsoft collaboration strengthens digital execution without distracting from consumer-health specialization.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Parental Leave
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Jefferies has raised its price target for Haleon to 410p from 400p, maintaining a Buy rating. The consumer health company, which owns brands including Sensodyne and Advil, beat margin expectations by 70 basis points in the first half. Haleon delivered organic sales growth of 3.1% in the second quarter. Oral Health grew 6.2%, driven by Sensodyne and Parodontax, whilst Pain Relief accelerated 4.6% on Voltaren gel expansion. However, Respiratory products declined 6.5% amid a weak cold and flu season. Gross margin expanded 140 basis points on productivity savings, lifting operating margin by 160 basis points to 24.3%. Jefferies noted North America returned to 3.1% growth, showing management-led turnaround gaining traction. The broker said Haleon needs growth exceeding 5% in the second half to reach its full year guidance midpoint.
Buymed x Haleon: A partnership milestone in Cambodia. * 1 day ago Buymed Receives Certificate of Appreciation from Haleon Strong partnerships are built through the work that happens every day: staying close to the market, coordinating openly, and finding practical ways to move forward together. That shared approach was recognised at Haleon's Pharmacist Event in Cambodia, where Buymed received a Certificate of Appreciation from Ms. Katrina Mangubat, General Manager of Haleon. The event was organised by Haleon to celebrate the pharmacist community and pharmacy partners who help bring trusted healthcare products closer to consumers across Cambodia. For Buymed and Haleon, the moment marked another step in a growing partnership. The certificate reflects the progress built together in the Cambodian market - through close coordination, consistent execution, and a shared commitment to respond to local needs. A celebration of the pharmacist community. At the heart of Haleon's Pharmacist Event was the pharmacist community and the pharmacy partners who help connect trusted healthcare products with people every day. The event created a valuable opportunity to recognise the relationships that support market progress. It brought together the people and organisations whose everyday work helps healthcare products reach consumers in ways that are relevant, reliable, and responsive to local needs. Buymed welcomed the opportunity to join the occasion alongside Haleon, the pharmacist community, and local stakeholders. The Certificate of Appreciation added a meaningful dimension to the event, acknowledging the trust and momentum that Buymed and Haleon have built together in Cambodia. A partnership built through everyday work. A certificate is presented in a single moment, but the partnership behind it takes shape over time. Buymed and Haleon have worked closely in Cambodia to turn shared plans into consistent market execution. That has meant staying connected to local realities, working through practical challenges together, and continuing to improve the way both teams operate across the market. The Certificate of Appreciation recognizes that journey. It reflects not only the outcomes of the partnership, but also the way those outcomes have been built: through open communication, reliable follow-through, and shared accountability from both sides. Partnership creates the most value when both sides bring their strengths together, stay close to the market, and keep building on what works. Building from Cambodia, growing across the region. The progress made in Cambodia gives the Buymed-Haleon partnership a strong foundation for what comes next. Buymed and Haleon will continue deepening their collaboration in Cambodia while expanding the partnership across Vietnam and Thailand. The next chapter will be shaped by the same principles that have guided the work so far: a close understanding of each market, consistent execution, and a willingness to keep learning and improving together. The aim is not to apply one formula everywhere, but to bring the partnership mindset to each market in a way that reflects local needs. For Buymed, this is how regional growth becomes meaningful - by building steadily in each market and creating progress that partners can sustain together. Looking ahead. The Certificate of Appreciation is a meaningful partnership milestone. More importantly, it is a reminder of the opportunity ahead: to build on the trust already established, strengthen collaboration further, and create the next set of results together. Buymed extends appreciation to Haleon, Ms. Katrina Mangubat, the pharmacist community, and the teams whose day-to-day work has contributed to this moment. Buymed looks forward to continuing the partnership across Cambodia, Vietnam, and Thailand.
Haleon's US subsidiary, Haleon US Capital LLC, has launched and priced a $2 billion fixed-rate bond offering. The offering comprises three tranches: $600 million in notes maturing in 2029 with a 4.625% coupon, $600 million in notes maturing in 2031 with a 4.875% coupon, and $800 million in notes maturing in 2036 with a 5.375% coupon. The offering is scheduled to settle on 21 August 2026. Payment of principal and interest is fully guaranteed by Haleon plc. The company plans to use the net proceeds, together with cash on hand if necessary, to repurchase its outstanding $1,999,350,000 3.375% fixed rate senior notes due March 2027 and for general corporate purposes. Barclays Capital, BofA Securities, Deutsche Bank Securities, Goldman Sachs and Mizuho Securities acted as joint book-running managers.
Daniela Cavinatto appointed general manager of Canada division for Haleon Canada. Daniela Cavinatto joins the consumer health company with more than 25 years of international leadership experience. Haleon Canada has appointed Daniela Cavinatto as its new general manager of the Canada division. Cavinatto joins the consumer health company with more than 25 years of international leadership experience. In her new position, she will lead Haleon's Canadian operations as the company works to strengthen its market leadership and expand its portfolio of consumer health brands, including Advil, Sensodyne, and Centrum. Industry experience across global markets. Prior to joining Haleon, Cavinatto served as general manager, Canada for The LEGO Group. During her time there, she led business growth by redefining market strategy, strengthening customer partnerships, and optimizing commercial investments. Throughout her career, Cavinatto has held senior executive roles across North America, Latin America, and Europe. Her background spans general management, sales, marketing, customer development, eCommerce, retail operations, and supply chain. "Daniela is an accomplished business leader with a proven ability to unlock growth, navigate complexity and deliver results in dynamic markets," said Nathalie Gerschtein, the Haleon North America president. "Canada is an important growth market for Haleon, and Daniela brings the commercial acumen, global perspective and leadership experience needed to help us build on our momentum. I am delighted to welcome Daniela to our North American leadership team and look forward to working with her as we strengthen our trusted brand portfolio and advance our leadership in consumer health." Portfolio reach and growth strategy. Haleon's Canadian product lineup holds a strong presence across retail channels. According to the company, six in 10 Canadian households rely on at least one Haleon brand. As of last year, the 2025 Product of The Year lineup included Tums Chewy Bites with Gas Relief. Cavinatto noted that the reach of the company's product line made the role an exciting opportunity. "Throughout my career, I've been inspired by opportunities to transform businesses, accelerate growth and help teams achieve ambitious goals," Cavinatto said. "That's what makes this opportunity so compelling. Haleon's portfolio of brands is rooted in science and consumer understanding with six in 10 Canadian households relying on at least one of our iconic brands. To lead a business with this kind of reach and impact is a true privilege and an opportunity that deeply inspires me." She added that she looks forward to working with internal teams, retail customers, and commercial partners to support the company's continued growth and innovation across Canada.
Haleon reported H1 2026 results ending 30 July, showing improved organic sales growth of 3.1% in Q2, with volume and mix up 1.4%. North America delivered strong progress at 3.1% growth, driven by shelf resets, innovation, and e-commerce momentum. Operating margin improved 120 basis points at constant currency, supported by supply chain efficiency and gross margin expansion of 140 basis points. Emerging markets achieved 6.3% growth in Q2, with India and Latin America leading performance. EPS grew 12% in H1. However, respiratory health remained weak, reducing organic growth by 150 basis points. Europe proved challenging with only 0.4% growth, whilst Middle East markets including Dubai and Pakistan experienced significant declines. The company acknowledged performing below its 4–6% medium-term growth target, with particular gaps in Europe and the Middle East.